Skip to main content

Advertisement

SpringerLink
Log in

Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia

  • Spotlight Correspondence
  • Published:
Leukemia Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

References

  1. Larson R . Imatinib (STI571, Gleevec™) as initial therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia (CML): results of a randomized phase III study vs interferon-alfa+cytarabine (IFN+AraC). Blood 2002; 100: 2a.

    Google Scholar 

  2. Sawyers C, Hochhaus A, Feldman E, Goldman J, Miller C, Ottmann O et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539.

    Article  CAS  Google Scholar 

  3. Druker B, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.

    Article  CAS  Google Scholar 

  4. Demetri G, von Mehren M, Blanke C, Van den Abbeele A, Eisenberg B, Roberts P et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472–480.

    Article  CAS  Google Scholar 

  5. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.

    Article  CAS  Google Scholar 

  6. Eming S, Whitsitt J, Krieg L, Morgan J, Davidson J . Particle-mediated gene transfer of PDGF isoforms promotes wound repair. J Invest Dermatol 1999; 112; 297–302.

    Article  CAS  Google Scholar 

  7. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed R, Heldin C et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61: 2929–2934.

    CAS  PubMed  Google Scholar 

  8. Ebnoether M, Stentoft J, Ford J, Buhl L, Gratwohl A . Cerebral oedema as a possible complication of treatment with imatinib. Lancet 2002; 359: 1751–1752.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematological Medicine, GKT School of Medicine, King's College Hospital, Denmark Hill Campus, London, UK

    D Milojkovic & G J Mufti

  2. Department of Dermatology, King's College Hospital, London, UK

    K Short, D Creamer & A W P du Vivier

  3. Department of Histopathology, GKT School of Medicine, Denmark Hill Campus, London, UK

    J R Salisbury

Authors
  1. D Milojkovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Short
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J R Salisbury
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Creamer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A W P du Vivier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G J Mufti
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Milojkovic, D., Short, K., Salisbury, J. et al. Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia. Leukemia 17, 1414–1416 (2003). https://doi.org/10.1038/sj.leu.2402991

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402991

  • Springer Nature Limited

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Search

Navigation